UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
|
|
|||
(State or other jurisdiction |
|
(Commission |
|
(I.R.S. Employer |
Nuvalent, Inc.
(Address of principal executive offices, including zip code)
(
(Registrant’s telephone number, including area code)
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
|
Trade |
|
Name of each exchange |
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 8.01. Other Events.
On May 16, 2024, Nuvalent, Inc. announced that the U.S. Food and Drug Administration granted breakthrough therapy designation to NVL-655 for the treatment of patients with locally advanced or metastatic anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer who have been previously treated with two or more ALK tyrosine kinase inhibitors.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
Nuvalent, Inc. |
||
|
|
|
||
Date: May 16, 2024 |
|
By: |
|
/s/ Deborah A. Miller |
|
|
|
|
Deborah A. Miller, Ph.D. |
|
|
|
|
Chief Legal Officer and Secretary |
Document and Entity Information |
May 16, 2024 |
---|---|
Cover [Abstract] | |
Amendment Flag | false |
Entity Central Index Key | 0001861560 |
Document Type | 8-K |
Document Period End Date | May 16, 2024 |
Entity Registrant Name | NUVALENT, INC. |
Entity Incorporation State Country Code | DE |
Entity File Number | 001-40671 |
Entity Tax Identification Number | 81-5112298 |
Entity Address, Address Line One | One Broadway |
Entity Address, Address Line Two | 14th Floor |
Entity Address, City or Town | Cambridge |
Entity Address, State or Province | MA |
Entity Address, Postal Zip Code | 02142 |
City Area Code | 857 |
Local Phone Number | 357-7000 |
Written Communications | false |
Soliciting Material | false |
Pre Commencement Tender Offer | false |
Pre Commencement Issuer Tender Offer | false |
Security 12b Title | Class A Common Stock, $0.0001 par value per share |
Trading Symbol | NUVL |
Security Exchange Name | NASDAQ |
Entity Emerging Growth Company | false |
RHY M_U=3_ 102P,$% @ 48&P6)>*NQS $P( L !?3T\ M$MP>:4#M.*2VBZD8_1!2:5K5N %(MB6/: (7->=I3W;+T]!;X"O.DQQ0FE(2S,.\,W2?S+W\PPU1>5* M(Y5;&GC3Y?YVX$G1H2)8%II%R=.B':5_'FR-9V87YTC'?8Q']>5=2(6NF9MYEJ6R!F_236P@R*2* MY U+2X 3[+O,&@EXN1:T/9=1,92L88!.R '<(Y_ A^[<#K3P&]'@!6^A C(,=D",Y1]XVXG\ M-/O4(VSV'T:$%'J6"V&%E+C?Z/F-:#R!+ ]=R_$)'0.M#,,SQ;;!<.AHQ$5V M9://8:Q#B'/Z3XRQJK"$52Q;#X&'' E<)S"D&IND53 >"CVN*!.L>@PL(:EU M&*ADMW,JI]=V<,TB]RI#FJ,,:&T'X:-:"Q4&L&]R( DNR94;4EWI>::W=Y-[ M2:AU[D&P]_ :C1W-CQ^W_ %02P,$% @ 48&P6"0>FZ*M ^ $ !H M !X;"]? +7_OR4Z?:!1W;J"V\R1&:P;*9,OL M[P"D6[2*+L[C,$]J%ZSB688&O-*]:A"2*+I!V#-DGNZ9HIP\_D-T==UI?#C] MLCCP#S"\7>BI160I2A4:Y$S":+8VP5+BRTR6HJ@R&8HJEG!:(.+)(&UI5GVP M3TZTYWD7-_=%KLWC":[?#'!X=/X!4$L#!!0 ( %&!L%AED'F2&0$ ,\# M 3 6T-O;G1E;G1?5'EP97-=+GAM;*V334[#,!"%KQ)E6R4N+%B@IAM@ M"UUP 6-/&JO^DV=:TMLS3MI*H!(5A4VL>-Z\SYZ7K-Z/$;#HG?78E!U1?!0" M50=.8ATB>*ZT(3E)_)JV(DJUDUL0]\OE@U#!$WBJ*'N4Z]4SM')OJ7CI>1M- M\$V9P&)9/(W"S&I*&:,U2A+7Q<'K'Y3J1*BY<]!@9R(N6%"*JX1<^1UPZGL[ M0$I&0[&1B5ZE8Y7HK4 Z6L!ZVN+*&4/;&@4ZJ+WCEAIC JFQ R!GZ]%T,4TF MGC",S[O9_,%F"LC*30H1.;$$?\>=(\G=560C2&2FKW@ALO7L^T%.6X.^D &PO=&AE;64O=&AE;64Q+GAM M;%!+ 0(4 Q0 ( %&!L%@:>*V.700 "H1 8 " @0X( M !X;"]W;W)K &PO &PO7W)E;',O=V]R:V)O;VLN>&UL M+G)E;'-02P$"% ,4 " !1@;!899!YDAD! #/ P $P M@ &W$@ 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08 "0 ) #X" !% " ! end
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